Condition
Endocrine Therapy clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Endocrine Therapy clinical trials that are recruiting, at sites in 3 countries (most in China (3), Japan (1), France (1)). By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest Endocrine Therapy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer | — | Grenoble | Recruiting | Mar 2, 2026 |
| Adjuvant abemaciclib plus hormone therapy after locoregional recurrence of HR-positive, HER2-negative breast cancer | Phase 3 | Koto-ku, Tokyo | Recruiting | Sep 24, 2025 |
| Evaluating the benefits of continued ovarian function suppression for breast cancer after 5 years | — | Wuhan, Hubei | Recruiting | Sep 22, 2023 |
| Combining CDK4/6 inhibitors with hormone therapy and what comes next for HR+/HER2- metastatic breast cancer | — | Changsha, Hunan | Recruiting | Sep 13, 2023 |
| Exploring cognitive impairment in breast cancer patients | — | Xi'an, Shaanxi | Recruiting | Mar 31, 2022 |
All recruiting trials (5)
-
Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer
This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.
-
Adjuvant abemaciclib plus hormone therapy after locoregional recurrence of HR-positive, HER2-negative breast cancer
This will test whether adding abemaciclib to standard hormone therapy helps people with HR-positive, HER2-negative breast cancer who have had their first locoregional recurrence.
-
Evaluating the benefits of continued ovarian function suppression for breast cancer after 5 years
This study is testing if continuing ovarian function suppression for premenopausal women with early hormone receptor positive breast cancer after 5 years helps them stay healthier compared to those who stop the treatment.
-
Combining CDK4/6 inhibitors with hormone therapy and what comes next for HR+/HER2- metastatic breast cancer
This study will see how different follow-up treatments work after progression on CDK4/6 inhibitors plus hormone therapy in people with HR+/HER2- metastatic breast cancer.
-
Exploring cognitive impairment in breast cancer patients
This study is trying to see if certain brain changes in young women with breast cancer who are undergoing chemotherapy and hormone therapy can help predict memory and thinking problems, so doctors can choose better treatment plans.
Related topics
Quick answers
How many Endocrine Therapy clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (3 trials), Japan (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.